Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico - 2Extreme Manual for Purchasing Your Next Truck
- 3Unwind: Four Extraordinary Spa Resorts On the planet
- 4More loons are filling Maine's lakes with their ghostlike calls
- 5Germany and trade unions kick off tough public-sector wage talks
- Find the Effect of Web-based Entertainment on Psychological wellness: Exploring the Advanced Scene Securely
- Daily Briefing: A bad flu season gets worse
- US FDA investigates Takeda's blood disorder drug after pediatric death
- He suddenly couldn't speak in space. NASA astronaut says his medical scare remains a mystery
- The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- Artemis II's moon-bound astronauts capture Earth's brilliant blue beauty as they leave it behind
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- Am I a Summer, or is this a scam? What I learned from color analysis.
- From Lounge chair to Money: Online Positions That Will Change Your Profession
